P2X7, a ligand-gated purinergic ion channel, has been at the center of intense efforts in the pharmaceutical industry in the last 15 years due to the growing appreciation of its role in inflammation. Since 2008–2009, increased focus on CNS available compounds has led to the publication of various patents on behalf of several pharmaceutical companies. This patent review aims at analyzing the recent patent literature (2008–2016) with a particular emphasis on those patents that are thought to deal with CNS penetrant compounds on the basis of their physicochemical features, the assays described in the patents and the uses these compounds are claimed for.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1 Volonte C, Apolloni S, D Skaper S, Burnstock G. P2X7 receptors: channels, pores and more. CNS Neurol. Disord. Drug Targets 11(6), 705–721 (2012).
Medline CASGoogle Scholar
2 Weisman GA, Camden JA, Peterson TS et al. P2 receptors for extracellular nucleotides in the central nervous system: role of P2X7 and P2Y2 receptor interactions in neuroinflammation. Mol. Neurobiol. 46(1), 96–113 (2012).
Medline CASGoogle Scholar
3 Alloisio S, Di Garbo A, Barbieri R et al. Evidence for two conductive pathways in P2X7 receptor: differences in modulation and selectivity. J. Neurochem. 113(3), 796–806 (2010).
Medline CASGoogle Scholar
4 Wei L, Caseley E, Li D, Jiang LH. ATP-induced P2X receptor-dependent large pore formation: how much do we know? Front. Pharmacol. 7, 5 (2016).
MedlineGoogle Scholar
5 Lenertz LY, Gavala M, Zhu Y, Bertics PJ. Transcriptional control mechanisms associated with the nucleotide receptor P2X7, a critical regulator of immunologic, osteogenic, and neurologic functions. Immunol. Res. 50(1), 22–38 (2011).
Medline CASGoogle Scholar
6 Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol. Rev. 87(2), 659–797 (2007).
Medline CASGoogle Scholar
7 Arulkumaran N, Unwin RJ, Tam FWK. A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opin Invest Drugs 20(7), 897–915 (2011).
Medline CASGoogle Scholar
8 Mesuret G, Engel T, Hessel EV et al. P2X7 receptor inhibition interrupts the progression of seizures in immature rats and reduces hippocampal damage. CNS Neurosci. Ther. 20(6), 556–564 (2014).
Medline CASGoogle Scholar
9 Suzuki K, Sugihara G, Ouchi Y et al. Microglial activation in young adults with autism spectrum disorder. JAMA Psychiatry 70(1), 49–58 (2013).
MedlineGoogle Scholar
10 Guile SD, Alcaraz L, Birkinshaw TN et al. Antagonists of the P2X7 receptor. From lead identification to drug development. J. Med. Chem. 52(10), 3123–3141 (2009).
Medline CASGoogle Scholar
11 Rech JC, Bhattacharya A, Letavi MA, Savall BM. The evolution of P2X7 antagonists with a focus on CNS indications. Bioorg. Med. Chem. Lett. 26(16), 3838–3845 (2016).
Medline CASGoogle Scholar
12 Bhattacharya A, Biber K. The microglial ATP-gated ion channel P2X7 as a CNS drug target. Glia 64(10), 1772–1787 (2016). •• Thorough and stimulant discussion over many open questions in P2X7 drug discovery.
MedlineGoogle Scholar
13 Charlton SJ, Vauquelin G. Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays. Br. J. Pharmacol. 161, 1250–1265 (2010).
Medline CASGoogle Scholar
14 Steinberg TH, Newman AS, Swanson JA, Silverstein SC et al. ATP4-permeabilizes the plasma membrane of mouse macrophages to fluorescent dyes. J. Biol. Chem. 262(18), 8884–8888 (1987).
Medline CASGoogle Scholar
15 Axxam S.p.A.: WO2015119018 (2015).
Google Scholar
16 Janssen Pharmaceutica NV: US20140275056 (2014).
Google Scholar
17 GlaxoSmithKline (GSK): WO2009074518 (2009). • One of the first patents specifically directed at CNS compounds. In vivo characterization of preferred examples
Google Scholar
18 He Y, Hara H, Núñez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem. Sci. 41(12), 1012–1021 (2016).
Medline CASGoogle Scholar
19 Shao BZ, Xu ZQ, Han BZ et al. NLRP3 inflammasome and its inhibitors: a review. Front. Pharmacol. 6, 262 (2015).
MedlineGoogle Scholar
20 Chrovian CC, Rech JC, Bhattacharya A, Letavic MA. P2X7 antagonists as potential therapeutic agents for the treatment of CNS disorders. Prog. Med. Chem. 53, 65–100 (2014). • Useful overview and discussion of the possible therapeutic indications of P2X7 antagonists.
Medline CASGoogle Scholar
21 Affectis Pharmaceuticals AG: WO2012163456 (2012). • In vivo characterization of preferred examples
Google Scholar
22 GlaxoSmithKline (GSK): WO2009053459A1 (2009).
Google Scholar
23 GlaxoSmithKline (GSK): WO2009074519A1 (2009).
Google Scholar
24 GlaxoSmithKline (GSK): WO2009077559A1.
Google Scholar
25 GlaxoSmithKline (GSK): WO201012501A1.
Google Scholar
26 H. Lundbeck A/S: WO2009108551A2 (2009).
Google Scholar
27 H. Lundbeck A/S: WO2014057078A1 (2014).
Google Scholar
28 H. Lundbeck A/S: WO2014057080A2 (2013).
Google Scholar
29 Neurogen Corporation: WO2009023623A1 (2009).
Google Scholar
30 Harris III et al. US20120157494A1 (2012).
Google Scholar
31 Schering Corporation: WO2012040048A2 (2013).
Google Scholar
32 Roche Palo Alto LLC: US20100160373A1 (2010).
Google Scholar
33 Roche Palo Alto LLC: US20100160384A1 (2010).
Google Scholar
34 Roche Palo Alto LLC: US20100160387A1 (2010).
Google Scholar
35 Roche Palo Alto LLC: US20100160388A1 (2010).
Google Scholar
36 Roche Palo Alto LLC: US20100160389A1 (2010).
Google Scholar
37 Hoffmann-La Roche AG: WO2011012592A1 (2011).
Google Scholar
38 Hoffmann-La Roche AG.: WO2011033055A1 (2011).
Google Scholar
39 Actelion Pharmaceuticals Ltd: WO2012114268A1 (2014).
Google Scholar
40 Actelion Pharmaceuticals Ltd: WO2013014587A1 (2013).
Google Scholar
41 Actelion Pharmaceuticals Ltd: WO2013108227A1 (2013).
Google Scholar
42 Actelion Pharmaceuticals Ltd: WO2014091415A1 (2014).
Google Scholar
43 Actelion Pharmaceuticals Ltd: WO2014097140A1 (2014).
Google Scholar
44 Actelion Pharmaceuticals Ltd: WO2014115072A1 (2014).
Google Scholar
45 Actelion Pharmaceuticals Ltd: WO2014115078A1 (2016).
Google Scholar
46 Janssen Pharmaceutica NV: WO2009132000A1 (2009).
Google Scholar
47 Janssen Pharmaceutica NV: US20140275015A1 (2014).
Google Scholar
48 Janssen Pharmaceutica NV: US20140275096A1 (2014).
Google Scholar
49 Janssen Pharmaceutica NV: US20140275120A1 (2014).
Google Scholar
50 Janssen Pharmaceutica NV: WO2016039977A1 (2016).
Google Scholar
51 Janssen Pharmaceutica NV: WO2016039983A1 (2016). • A detailed pharmacological section of the patent is included to characterize new P2X7 antagonists
Google Scholar
52 Affectis Pharmaceuticals AG: WO2012110190A1 (2009).
Google Scholar
53 Affectis Pharmaceuticals AG: WO2012163792A1 (2012).
Google Scholar
54 Affectis Pharmaceuticals AG: US20130197046 (2014).
Google Scholar
55 Park JH, Kim YC. P2X7 receptor antagonists: a patent review (2010–2015). Exp. Opin. Ther. Pat. doi:10.1080/13543776.2017.1246538 (2016) (Epub ahead of print).
Google Scholar

Vol. 6, No. 2

Metrics

Downloaded 216 times

History

Published online 1 March 2017

Published in print March 2017

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download

P2X7 antagonists for CNS indications: recent patent disclosures

Abstract

References